Zhongyuan Union Cell & Gene Engineering (SHSE:600645) Total Equity: ¥3,767 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600645 Zhongyuan Union Cell & Gene Engineering Corp Ltd SHSE:600645
60 GF Score
Price ¥17.92
GF Value ¥20.36
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Zhongyuan Union Cell & Gene Engineering Total Equity?

Zhongyuan Union Cell & Gene Engineering SHSE:600645 -6.18% 60 Total Equity is ¥3,767 Mil as of Mar. 2026. GuruFocus rates SHSE:600645 with a GF Score™ of 60/100 and a GF Value™ of ¥20.36 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Zhongyuan Union Cell & Gene Engineering's total equity for the quarter that ended in Mar. 2026 was ¥3,767 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Zhongyuan Union Cell & Gene Engineering Total Equity Historical Data

* Premium members only.

The historical data trend for Zhongyuan Union Cell & Gene Engineering's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zhongyuan Union Cell & Gene Engineering Total Equity Chart

Zhongyuan Union Cell & Gene Engineering Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3,532.76 3,653.65 3,798.61 3,659.07 3,754.81

Zhongyuan Union Cell & Gene Engineering Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3,682.73 3,709.05 3,761.66 3,754.81 3,767.31
SHSE:600645
60GF Score
Zhongyuan Union Cell & Gene Engineering Corp Ltd SHSE:600645
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zhongyuan Union Cell & Gene Engineering Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Zhongyuan Union Cell & Gene Engineering's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=5292.252-1537.446
=3,755

Zhongyuan Union Cell & Gene Engineering's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=5265.07-1497.763
=3,767

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of ¥3,767 Mil mean?
Zhongyuan Union Cell & Gene Engineering (SHSE:600645) has a Total Equity of ¥3,767 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Zhongyuan Union Cell & Gene Engineering and its competitors.
Is Zhongyuan Union Cell & Gene Engineering's Total Equity too high?
Zhongyuan Union Cell & Gene Engineering's current Total Equity is ¥3,767 Mil. Overall, Zhongyuan Union Cell & Gene Engineering has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zhongyuan Union Cell & Gene Engineering's Total Equity compare to VRTX and REGN?
Zhongyuan Union Cell & Gene Engineering's Total Equity of ¥3,767 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Zhongyuan Union Cell & Gene Engineering and its competitors. Zhongyuan Union Cell & Gene Engineering's current Total Equity is ¥3,767 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhongyuan Union Cell & Gene Engineering stock overvalued right now?
Based on GuruFocus' analysis, Zhongyuan Union Cell & Gene Engineering (SHSE:600645) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥20.36, compared to a current price of ¥17.92 — trading 12% below its estimated fair value. The current Total Equity is ¥3,767 Mil. Zhongyuan Union Cell & Gene Engineering's overall GF Score™ is 60/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Zhongyuan Union Cell & Gene Engineering (SHSE:600645), the current Total Equity is ¥3,767 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zhongyuan Union Cell & Gene Engineering (SHSE:600645) Overvalued in 2026?

Based on GuruFocus' analysis, Zhongyuan Union Cell & Gene Engineering stock appears to be undervalued. The current stock price of ¥17.92 is trading 12% below its estimated GF Value™ of ¥20.36. GuruFocus considers Zhongyuan Union Cell & Gene Engineering to be Modestly Undervalued.

Key valuation signals for SHSE:600645:

  • Total Equity: ¥3,767 Mil
  • GF Value™: ¥20.36 vs. price of ¥17.92 (12% below fair value)
  • GF Score™: 60/100 with 2 warning signs

No single metric tells the full story. See the SHSE:600645 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zhongyuan Union Cell & Gene Engineering Business Description

Address 45 East of Tianjin Airport Economic Zone nine, Tianjin, CHN, 300304
Zhongyuan Union Cell & Gene Engineering Corp Ltd is engaged in stem cell technology research, as well as detection and storage sources of stem cells in China. The company insists on the core strategy upon dual-core development of 'cell + gene' with the major businesses covering various cell storage businesses of newborns and adults; the preparation and storage of cord blood hematopoietic stem cells, umbilical cord mesenchymal stem cells, placental pluripotent stem cells, adipose-derived stem cells and immune cells; genetic testing services relating to children's genes.
60GF Score

Get the complete analysis for SHSE:600645

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥17.92
Price
¥20.36
GF Value